ISB News

Promotion: Dr. Jie Luo Becomes Senior Research Scientist

Congratulations to Dr. Jie Luo, of the Ranish Lab, who has been promoted to senior research scientist. From Dr. Jeff Ranish:

Jie Luo is an extremely dedicated and talented scientist. When he joined ISB in 2006 as a postdoctoral fellow, he had no experience in mass spectrometry-based proteomics. Now he is a leader in the field of structural and functional proteomics. He has conceptualized and implemented several innovative proteomics strategies for studying protein-protein interactions (PPIs) in macromolecular assemblies, and he is currently developing technology to study PPIs on a large scale.  Jie is also quite interactive, collaborating with researchers throughout the world to study the architecture of macromolecular assemblies. A good example of his work can be seen in his recent paper on the architecture of the general transcription and DNA repair factor TFIIH (Luo, et al., Molecular Cell, 2015).

Jie excels at pushing the boundaries of system biology research, and he does it while maintaining a positive attitude. Jie is valuable asset to ISB and it is a pleasure to work with him.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.